(Q38805382)

6 September 2017

1 reference

title

Therapy implications of the role of interleukin-2 in cancer (English)

1 reference

6 September 2017

Paolo Lissoni

1

1 reference

6 September 2017

26 October 2016

1 reference

Expert Review of Clinical Immunology

6 September 2017

1 reference

6 September 2017

13

1 reference

6 September 2017

5

1 reference

6 September 2017

491-498

1 reference

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

6 September 2017

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2017.1245146

Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2017.1245146

Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2017.1245146

Regulatory T cells, tumour immunity and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2017.1245146

Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2017.1245146

IL-12 inhibits the TGF-β-dependent T cell developmental programs and skews the TGF-β-induced differentiation into a Th1-like direction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2017.1245146

The interleukin-17 cytokine family: critical players in host defence and inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2017.1245146

IL-21 inhibits T cell IL-2 production and impairs Treg homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2017.1245146

Positive and negative influences of regulatory T cells on tumour immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2017.1245146

Psychoneuroendocrine Influences on Immunocompetence and Neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2017.1245146

Cell-cell communication in carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2017.1245146

The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2017.1245146

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2017.1245146

Circadian-system alterations during cancer processes: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2017.1245146

In vivo stimulation of IL-12 secretion by subcutaneous low-dose IL-2 in metastatic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2017.1245146

Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2017.1245146

Cancer, cytokines, and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2017.1245146

Multicenter phase 2 study of interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2017.1245146

Apparent involvement of opioid peptides in stress-induced enhancement of tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2017.1245146

Antiproliferative effect of pineal indoles on cultured tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2017.1245146

PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2017.1245146

Interleukin-15 in the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2017.1245146

The clinical neuroimmunotherapeutic role of melatonin in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2017.1245146

Cannabinoids as novel anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2017.1245146

10.1080/1744666X.2017.1245146

21 January 2018

Identifiers

DOI

1 reference

6 September 2017

1 reference

PubMed ID

27782752